Emerging breakthroughs and future prospects of Claudin18.2 in targeted therapy and immuno-therapy for gastric cancer
10.3760/cma.j.cn115610-20250206-00045
- VernacularTitle:Claudin 18.2在胃癌靶向免疫治疗中的新突破与展望
- Author:
Jiayu JIANG
1
;
Zhen FANG
;
Kexin ZHENG
;
Baoshan CAI
;
Yulong ZHAO
;
Zhaodong LIU
;
Changqing JING
;
Leping LI
;
Liang SHANG
Author Information
1. 山东第一医科大学附属省立医院胃肠外科，济南 250021
- Publication Type:Journal Article
- Keywords:
Stomach neoplasms;
Claudin 18.2;
Targeted therapy;
Immunotherapy;
Biomarkers
- From:
Chinese Journal of Digestive Surgery
2025;24(3):343-349
- CountryChina
- Language:Chinese
-
Abstract:
Gastric cancer, a highly malignant tumor, has seen a persistent rise in global incidence in recent years. Claudin 18.2, a protein with highly specific expression in gastric cancer, has emerged as a prominent research target in therapeutic development. The overexpression of Claudin 18.2 in gastric cancer cells and its abnormal surface exposure provide novel opportunities for targeted and immunotherapeutic interventions. Therapeutic approaches targeting Claudin 18.2 have shown promising initial results in clinical trials, primarily including monoclonal antibodies and chimeric antigen receptor T-cell therapies. The authors systematically summarize the biological characteristics, mechanism of action, clinical research progress, and future treatment prospects and challenges of Claudin 18.2.
